Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Waterborne aripiprazole blunts the stress response in zebrafish.

Barcellos HH, Kalichak F, da Rosa JG, Oliveira TA, Koakoski G, Idalencio R, de Abreu MS, Giacomini AC, Fagundes M, Variani C, Rossini M, Piato AL, Barcellos LJ.

Sci Rep. 2016 Nov 22;6:37612. doi: 10.1038/srep37612.

2.

A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution.

Heitzmann E, Javelot H, Weiner L, Michel B.

Case Rep Psychiatry. 2016;2016:7031245.

3.

Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.

Deutschländer A, la Fougère C, Boetzel K, Albert NL, Gildehaus FJ, Bartenstein P, Xiong G, Cumming P.

Neuroimage Clin. 2016 Jun 9;12:41-6. doi: 10.1016/j.nicl.2016.06.007.

4.

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.

Li P, Snyder GL, Vanover KE.

Curr Top Med Chem. 2016;16(29):3385-3403. Review.

5.

Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study.

Becker G, Bolbos R, Costes N, Redouté J, Newman-Tancredi A, Zimmer L.

Sci Rep. 2016 May 23;6:26633. doi: 10.1038/srep26633.

6.

Low-dose aripiprazole monotherapy in a young child with disruptive mood dysregulation disorder.

Averna R, D'Agati E, Vicari S.

Ther Adv Psychopharmacol. 2016 Apr;6(2):149-51. doi: 10.1177/2045125315591927. No abstract available.

7.

Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole.

Başay Ö, Basay BK, Öztürk Ö, Yüncü Z.

Clin Psychopharmacol Neurosci. 2016 May 31;14(2):221-5. doi: 10.9758/cpn.2016.14.2.221.

8.

Role of Dopamine 2 Receptor in Impaired Drug-Cue Extinction in Adolescent Rats.

Zbukvic IC, Ganella DE, Perry CJ, Madsen HB, Bye CR, Lawrence AJ, Kim JH.

Cereb Cortex. 2016 Jun;26(6):2895-904. doi: 10.1093/cercor/bhw051.

9.

Extrapyramidal side-effects of low-dose aripiprazole in an 11-year-old child.

Mohapatra S.

J Neurosci Rural Pract. 2016 Jan-Mar;7(1):141-2. doi: 10.4103/0976-3147.165355.

10.

Brexpiprazole: so far so good.

Das S, Barnwal P, Winston A B, Mondal S, Saha I.

Ther Adv Psychopharmacol. 2016 Feb;6(1):39-54. doi: 10.1177/2045125315614739. Review.

11.

Aripiprazole: from pharmacological profile to clinical use.

Di Sciascio G, Riva MA.

Neuropsychiatr Dis Treat. 2015 Oct 13;11:2635-47. doi: 10.2147/NDT.S88117. Review.

12.

Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.

Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, Dew MA, Butters MA, Stack JA, Begley AE, Reynolds CF 3rd.

Lancet. 2015 Dec 12;386(10011):2404-12. doi: 10.1016/S0140-6736(15)00308-6. Erratum in: Lancet. 2015 Dec 12;386(10011):2394.

13.

Clinical pharmacology of atypical antipsychotics: an update.

Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, Altamura AC.

EXCLI J. 2014 Oct 13;13:1163-91. Review.

14.

Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism.

de Bartolomeis A, Tomasetti C, Iasevoli F.

CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3. Review.

15.

Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

Nakajima S, Takeuchi H, Plitman E, Fervaha G, Gerretsen P, Caravaggio F, Chung JK, Iwata Y, Remington G, Graff-Guerrero A.

Schizophr Res. 2015 May;164(1-3):164-75. doi: 10.1016/j.schres.2015.01.043. Review.

17.

Ventral striatum binding of a dopamine D2/3 receptor agonist but not antagonist predicts normal body mass index.

Caravaggio F, Raitsin S, Gerretsen P, Nakajima S, Wilson A, Graff-Guerrero A.

Biol Psychiatry. 2015 Jan 15;77(2):196-202. doi: 10.1016/j.biopsych.2013.02.017. Erratum in: Biol Psychiatry. 2015 Mar 15;77(6):597.

18.

Tardive dyskinesia: treatment with aripiprazole.

Kang NR, Kim MD.

Clin Psychopharmacol Neurosci. 2011 Apr;9(1):1-8. doi: 10.9758/cpn.2011.9.1.1.

19.

Aripiprazole Improved Obsessive Compulsive Symptoms in Asperger's Disorder.

Celik G, Tahiroglu AY, Firat S, Avci A.

Clin Psychopharmacol Neurosci. 2011 Dec;9(3):134-6. doi: 10.9758/cpn.2011.9.3.134.

20.

Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action.

Roberts PD, Spiros A, Geerts H.

Alzheimers Res Ther. 2012 Nov 26;4(6):50. doi: 10.1186/alzrt153.

Supplemental Content

Support Center